ERBB2 and breast cancer: To further explore the conflicting findings in BC, we analyzed RRM2B amplifications separately in each of the three major subtypes of breast cancer [ER + PR + HER2 + (n = 86), ER + PR + HER2- (n = 334), and triple negative ER-PR-HER2- (n = 100)].